HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Vermont Chemical Bill; USDA “Made With Organic”; Hair Care In Brazil; More

This article was originally published in The Rose Sheet

Executive Summary

A Vermont bill awaiting the governor’s signature would require manufacturers of consumer products used by children, including cosmetics, to report use of chemicals of concern and potentially mandate labeling changes; USDA clarifies requirements for “made with organic” claims under the National Organic Program. More news in brief.

You may also be interested in...



EC Proposes Harmonizing Cosmetics Safety, Labeling With U.S. Through TTIP

As negotiators from the U.S. and the European Commission continue discussing ways to further trade between the two regions as part of the Transatlantic Trade and Investment Partnership, the EC recommends a “regulatory convergence” for the cosmetics sector. In a position paper, the EC proposes mutual recognition of lists of prohibited and allowed substances in cosmetics, among other measures.

Dr. Bronner’s V. USDA? Firm Meets With Agency On “Organic” To Avoid Suit

Dr. Bronner’s Magic Soaps petitions USDA to enforce its NOP requirements in areas of the cosmetics market, in particular, that have not been addressed by Whole Foods’ 2011 policy for organic personal care. Firm also requests clarification on the agency’s position related to organic claims by way of brand names, hoping to galvanize USDA action and avoid litigation.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.

UsernamePublicRestriction

Register

RS019037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel